LENZ Therapeutics (LENZ) Insider Drapkin Buys 22,100 Shares
Kimberlee Drapkin picked up 22,100 shares of LENZ Therapeutics, Inc. on June 15, 2026, part of a coordinated round of insider activity.
Reviewed by automated data checks against the source filing. How we make and check alerts
Kimberlee Drapkin bought 22,100 shares of LENZ Therapeutics, Inc. ($LENZ) on June 15, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $LENZ is down 12.2% after 1 week, down 24.7% after 1 month and down 50.7% to date (from the $6.63 close on Jun 15, 2026).
LENZ
LENZ Therapeutics, Inc.
Key Points
- Kimberlee Drapkin acquired 22,100 shares of LENZ Therapeutics, Inc. NasdaqGS:LENZ on June 15, 2026.
- The transaction formed part of a broader round of insider purchases that included multiple key stakeholders buying identical blocks.
- Wall Street coverage features a consensus mean price target of $24.00 across seven active analyst opinions.
Get $LENZ trade alerts by text
We text you when insiders, Congress or big funds trade $LENZ. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated LENZ Therapeutics, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at LENZ Therapeutics, Inc.
Kimberlee Drapkin added to holdings in LENZ Therapeutics, Inc. NasdaqGS:LENZ on June 15, 2026, picking up 22,100 shares. This transaction arrived alongside a coordinated round of purchases from several other insiders who also secured identical blocks on the same date.
Group Purchases Span Multiple Key Insiders
The June 15, 2026 transaction matched moves made by L.P. Ra Capital Management, Jeffrey George, Shelley Thunen, James McCollum, Frederic Guerard, and Zachary Scheiner. Each of these participants acquired 22,100 shares on that day, reflecting parallel decisions across the stakeholder group.
LENZ Stock Trades Near Moving Averages
Shares of LENZ recently changed hands at $6.77, sitting above its 50-day moving average of $5.01 while remaining below its 200-day moving average of $10.27. The equity has moved between a 52-week low of $4.00 and a 52-week high of $50.40.
Recent Earnings and Financial Position
For its recent reporting period, LENZ Therapeutics posted revenue of $21.47 million alongside a revenue growth rate of 9.7%. The firm reported an earnings per share figure of -$4.13 and a return on equity of -59.2%. The next earnings update is scheduled for November 4, 2026.
Analysts Set New Price Targets
Coverage from financial institutions includes Piper Sandler, which maintained a neutral rating on August 12, 2026, and moved its price target to $7.00 from $12.00. Earlier, on July 7, 2026, HC Wainwright & Co. reiterated a buy rating with a price target of $38.00. Across seven analyst opinions, the mean price target rests at $24.00, with high estimates reaching $60.00 and low targets starting at $7.00.
Overview of LENZ Therapeutics
Headquartered in Solana Beach, California, LENZ Therapeutics operates as a commercial-stage pharmaceutical enterprise focused on developing therapies intended to improve adult vision. Its primary product candidates target the treatment of presbyopia.
What to Watch Next for LENZ
Market participants will likely track upcoming regulatory updates and the scheduled November 4, 2026 earnings report for further clarity on commercial progress. Additional Form 4 filings will reveal whether insider buying trends continue through the second half of the year.
Related Filing Alerts
Source: Kimberlee Drapkin's Form 4 filing on $LENZ (Jun 15, 2026). Find the original filing: LENZ Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts